Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2020-05-29 Director's Dealing
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for 'notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It identifies a specific executive (Adam Steensberg), the issuer (Zealand Pharma A/S), and details a sale of shares. This matches the definition for Director's Dealing (DIRS).
2020-05-29 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document is titled 'Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons'. This is a standard regulatory disclosure for insider trading or director dealings, which corresponds to the 'Director's Dealing' category.
2020-05-29 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document is an announcement regarding transactions in company shares by persons discharging managerial responsibilities (PDMRs). While it mentions that the details are in the attached files, the primary purpose of this specific text is to report insider/director dealings as required by market abuse regulations. Therefore, it falls under the 'Director's Dealing' category.
2020-05-29 English
Director's Dealing 2020
Director's Dealing Classification · 99% confidence The document is explicitly titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details a transaction (Exercise of warrants) by an executive (Adam Steensberg, EVP, Chief Medical and Development Officer) of the issuer (Zealand Pharma A/S). This perfectly matches the definition of Director's Dealing (insider trades by executives/directors), which corresponds to the code DIRS.
2020-05-29 English
Zealand Pharma announces FDA acceptance of New Drug Application for the dasiglucagon HypoPal® rescue pen for treatment of severe hypoglycemia
Regulatory Filings Classification · 95% confidence The document is a press release from Zealand Pharma announcing the FDA's acceptance of a New Drug Application (NDA). While it contains information about a regulatory milestone, it does not fit into specific categories like financial reports, board changes, or shareholder voting. It is a general corporate announcement regarding business operations and regulatory progress. According to the provided definitions, 'Regulatory Filings' (RNS) serves as the fallback category for miscellaneous announcements that do not fit into more specific buckets like M&A, dividends, or earnings releases.
2020-05-22 English
Earnings Release 2020
Earnings Release Classification · 95% confidence The document is a press release announcing that the FDA has accepted the New Drug Application (NDA) for dasiglucagon HypoPal® rescue pen and provides a PDUFA target action date. This type of announcement, detailing regulatory progress, clinical trial success, and future outlook, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific management/board change, it fits best as an Earnings Release (ER) as these often contain key operational and regulatory milestones alongside financial highlights, or potentially a Regulatory Filing (RNS) if it were purely administrative. Given the focus on a major regulatory milestone (NDA acceptance) and the structure typical of a press release, ER is the most appropriate fit among the specific options, as ERs often include significant pipeline updates. However, since it is a specific announcement about a regulatory event (NDA acceptance) rather than quarterly financial results, and it is a short press release, it could also be considered a Regulatory Filing (RNS) if ER is reserved strictly for financial results. Given the context of a major drug development milestone announcement, ER is often used for these types of positive news releases. I will classify it as ER, as it functions as a key update release. Q2 2020
2020-05-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.